Non-small cell lung cancer
Not recruitingStudy Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression
Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+3
Italy- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Astrazeneca AB










